Back to top
more

Cidara Therapeutics (CDTX)

(Delayed Data from NSDQ)

$13.09 USD

13.09
28,569

+0.39 (3.07%)

Updated May 14, 2024 04:00 PM ET

After-Market: $13.07 -0.02 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CDTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cidara Therapeutics, Inc. [CDTX]

Reports for Purchase

Showing records 21 - 40 ( 144 total )

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

12/02/2022

Daily Note

Pages: 5

Foundational CoM U.S. Patent Granted For CD388; Lancet Publication Highlights Rezafungin Pivotal Dataset; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

11/25/2022

Daily Note

Pages: 3

Rezafungin AdCom Set for January 24; We Anticipate an Unequivocally Positive Vote and a Meaningful CDTX Catalyst

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

11/07/2022

Company Report

Pages: 8

3Q Recap; Approaching Rezafungin PDUFA on March 22, 2023; Phase 2a CD388 Influenza Data in 1H23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

09/21/2022

Daily Note

Pages: 3

Rezafungin PDUFA Date March 22, 2023, Under Priority Review; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

09/14/2022

Daily Note

Pages: 3

First Healthy Volunteer Dosed in Phase 2a Study of CD388 As Influenza Prophylactic; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

08/11/2022

Company Report

Pages: 8

2Q Recap; Awaiting NDA Acceptance to Confirm PDUFA Date; Updating Model Based on Melinta Agreement; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

07/28/2022

Daily Note

Pages: 4

Rezafungin NDA Submitted, PDUFA Expected in 1Q23; New Partner Melinta to Commercialize in the U.S.; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

07/14/2022

Daily Note

Pages: 5

Biotechnology - Dropping Coverage of Entasis Therapeutics (ETTX) and Cidara Therapeutics (CDTX)

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

07/08/2022

Daily Note

Pages: 5

R&D Day Highlights Cloudbreak Platform''s Potential in Two Major Therapeutic Areas; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

07/05/2022

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

05/12/2022

Company Report

Pages: 8

1Q22 Recap: Awaiting NDA Filing in Mid-2022; Phase 1 Safety and PK Data on CD388 in 2H22; Moderate PT to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

04/26/2022

Daily Note

Pages: 4

ECCMID Presentations Highlight Rezafungin''s Safety

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

03/31/2022

Daily Note

Pages: 3

CD388 Phase 1 Trial Kicks Off As Expected; Dosing of First Cohort Already Completed; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

03/10/2022

Company Report

Pages: 6

Q4 Financials; CD388 IND Filed; NDA Filing for Rezafungin on Track for Mid-2022

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

03/10/2022

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

03/08/2022

Company Report

Pages: 8

4Q Recap; Rezafungin Regulatory Filings On Target for Mid-2022; Phase 1 Study of CD388 Begins in 1Q22; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

03/04/2022

Daily Note

Pages: 3

Rezafungin''s PIM Designation May Enable Its Use in the U.K. Prior to Regulatory Approval; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

02/14/2022

Daily Note

Pages: 3

CD388 to Enter the Clinic For Seasonal and Pandemic Influenza With IND Acceptance; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

12/16/2021

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

12/16/2021

Company Report

Pages: 6

Ph 3 Data ReSTOREs the Faith

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party